Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus Chemotherapy in Second-line Advanced NSCLC
NCT03256721Phase 2Terminated
- Sponsor
- 900th Hospital of Joint Logistics Support Force of PLA
- Start
- Aug 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by 900th Hospital of Joint Logistics Support Force of PLA. Primary endpoint: Progression-Free Survival at 6 months. Started Aug 2017; status: terminated.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03256721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03256721.